Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Towards Biomarkers and Pathophysiology of Pulmonary Hypertension in Myeloproliferative Neoplasms

Franco Castillo Tokumori, Daniel C Choi, Pouneh Kermani, Katie Erdos, Alexander Gazda, Nathaniel Robichaud, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 6561.

https://doi.org/10.1182/blood-2024-209500

Published: 2024

Journal Articles

Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood (2024) 144 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2024-200997

Published: 2024

Journal Articles

Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera

Alexander Gazda, Di Pan, Katie Erdos, Ghaith Abu-Zeinah, Alexandra Racanelli, Evelyn Horn, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 3172.

https://doi.org/10.1182/blood-2024-210231

Published: 2024

Journal Articles

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Blood (2024) 144 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2024-200999

Published: 2024

Journal Articles

Deep Learning Predicts JAK2 , Calr TET2 , and ASXL1 directly from Whole Slide Marrow Images

Spencer Krichevsky, Yuwei Zhang, Madhu M Ouseph, Tahmeena Ahmed, Ghaith Abu-Zeinah, Joseph M. Scandura, Rajarsi Gupta

Blood (2024) 144 (Supplement 1): 3600.

https://doi.org/10.1182/blood-2024-208380

Published: 2024

Journal Articles

Correlating Image-Level Nucleomorphologic Features with Molecular Subtypes of Myeloproliferative Neoplasms

Spencer Krichevsky, Madhu M Ouseph, Yuwei Zhang, Tahmeena Ahmed, Ghaith Abu-Zeinah, Joseph M. Scandura, Rajarsi Gupta

Blood (2024) 144 (Supplement 1): 3613.

https://doi.org/10.1182/blood-2024-208329

Published: 2024

Journal Articles

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 6629.

https://doi.org/10.1182/blood-2024-200268

Published: 2024

Journal Articles

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Blood (2024) 144 (Supplement 1): 655.

https://doi.org/10.1182/blood-2024-200312

Published: 2024

Journal Articles

DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha

Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Jr., Richard T. Silver, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 3190.

https://doi.org/10.1182/blood-2024-210703

Published: 2024

Journal Articles

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Neville Lee, Jr., Katie Erdos, Aqib Abdul Rahman, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood (2024) 144 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2024-211143

Published: 2024

Journal Articles

Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera

Katie Erdos, Neville Lee, Jr., Yushu Shi, Ghaith Abu-Zeinah, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2024-210632

Published: 2024

Journal Articles

Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

Daniel C Choi, Nassima Messali, Ghaith Abu-Zeinah, Pouneh Kermani, Maria Mia Yabut, Franco Castillo Tokumori, Katie Erdos, Joseph M. Scandura, Narasimha Rao Uda, Heidi Lischer, Thomas Lehmann, Marta Sobas, Tata Nageswara Rao

Blood (2024) 144 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2024-212169

Published: 2024

Journal Articles

MPN Fitness: A Single-Cell, Single-Tube Measurement of the Pathobiology of MPNs

Franco Castillo Tokumori, Daniel C Choi, Ghaith Abu-Zeinah, Nassima Messali, Maria Mia Yabut, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 1761.

https://doi.org/10.1182/blood-2024-209523

Published: 2024

Journal Articles

Importance of Diagnosing Polycythemia Vera (PV) Patients (pts) Whose Hematocrit (HCT)/Hemoglobin (HGB) Are Less Than the Who 2022 Stipulated Criteria

Neville Lee, Jr., Katie Erdos, Joseph M. Scandura, Ghaith Abu-Zeinah, Richard T. Silver

Blood (2023) 142 (Supplement 1): 6434.

https://doi.org/10.1182/blood-2023-189643

Published: 2023

Journal Articles

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)

Joseph M. Scandura, Aaron T. Gerds, Ellen K. Ritchie, Xulong Wang, Steve Kye, Raajit K. Rampal

Blood (2023) 142 (Supplement 1): 3211.

https://doi.org/10.1182/blood-2023-181720

Published: 2023

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

Capturing Endothelial-to-Hematopoietic Transition Using a Highly Efficient in Vitro Platform

Nassima Messali, Mia Yabut, Pouneh Kermani, Shahin Rafii, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2023-190072

Published: 2023

Journal Articles

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Nima Ghalehsari, Zhengming Chen, Sebastian A. Mayer, Ghaith Abu-Zeinah, Tsiporah B. Shore, Ellen K. Ritchie, Richard T. Silver, Andrew I. Schafer, Joseph M. Scandura, Gail J. Roboz, Koen Van Besien, Alexandra Gomez-Arteaga

Blood (2023) 142 (Supplement 1): 6953.

https://doi.org/10.1182/blood-2023-185075

Published: 2023

Journal Articles

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Katie Erdos, Madhu M Ouseph, Julia Geyer, Neville Lee, Jr., Ghaith Abu-Zeinah, Joseph M. Scandura, Richard T. Silver

Blood (2023) 142 (Supplement 1): 3198.

https://doi.org/10.1182/blood-2023-187769

Published: 2023

Journal Articles

Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera

Spencer Krichevsky, Ghaith Abu-Zeinah, Katie Erdos, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2023-190684

Published: 2023

NARROW

Towards Biomarkers and Pathophysiology of Pulmonary Hypertension in Myeloproliferative Neoplasms

Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Deep Learning Predicts JAK2 , Calr TET2 , and ASXL1 directly from Whole Slide Marrow Images

Correlating Image-Level Nucleomorphologic Features with Molecular Subtypes of Myeloproliferative Neoplasms

A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera

Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

MPN Fitness: A Single-Cell, Single-Tube Measurement of the Pathobiology of MPNs

Importance of Diagnosing Polycythemia Vera (PV) Patients (pts) Whose Hematocrit (HCT)/Hemoglobin (HGB) Are Less Than the Who 2022 Stipulated Criteria

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Capturing Endothelial-to-Hematopoietic Transition Using a Highly Efficient in Vitro Platform

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only